Cellyan Biotechnology (HKPD) Fundamental Analysis: Revenue, Earnings & Valuation

3.69 / 10

Netural

The equity presents concerning fundamental picture (3.7/10). Strengths include Net profit attributable to parent company shareholders (YoY growth rate %) and Basic earnings per share (YoY growth rate %), with caution warranted for Net cash flow from operating activities (YoY growth rate %) and Total profit (YoY growth rate %). This merits prudent consideration.

Analysis Checks(3/6)

Net cash flow from operating activities per share (YoY growth rate %)

Value54730.27

Score1/3

Weight34.14%

1M Return2.70%

Basic earnings per share (YoY growth rate %)

Value-101.67

Score2/3

Weight21.99%

1M Return1.77%

Total profit (YoY growth rate %)

Value-97.63

Score1/3

Weight20.37%

1M Return1.58%

Net cash flow from operating activities (YoY growth rate %)

Value244.35

Score0/3

Weight-35.86%

1M Return-3.38%

Diluted earnings per share (YoY growth rate %)

Value-101.67

Score2/3

Weight16.81%

1M Return1.35%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value-102.03

Score2/3

Weight42.55%

1M Return3.29%

Is HKPD fundamentally strong?

HKPD scores 3.69/10 on fundamentals and holds a Fair valuation at present. Backed by its 3.03% ROE, -4.29% net margin, -20.83 P/E ratio, 2.84 P/B ratio, and -131.72% earnings growth, these metrics solidify its Netural investment rating.